The university’s asymptomatic testing program utilizes the commercially available TaqPath RT-PCR COVID-19 kit, developed and marketed by Thermo Fisher Scientific.
In connection with the asymptomatic testing program, the university has designated an ordering provider within the university’s Public Health Central Command Center who interfaces with Shield T3.
A copy of the validation report is available here.
Testing samples are disposed of as medical waste and are not saved/stored by either Vanderbilt or Shield T3. Information about the university’s approach to protection of privacy in connection with its COVID-19 protocols, including testing through Shield T3, is available here.
In addition, the university’s contractual agreement with Shield T3 requires Shield T3 to comply with applicable federal and state privacy and security laws and regulations, including the Health Insurance Portability and Accountability Act of 1996 and the Family Educational Rights and Privacy Act.